{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T19:15:37Z","timestamp":1793301337450,"version":"4.5.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,7]],"date-time":"2016-10-07T00:00:00Z","timestamp":1475798400000},"content-version":"vor","delay-in-days":1010,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1038\/mt.2013.216","type":"journal-article","created":{"date-parts":[[2013,9,12]],"date-time":"2013-09-12T11:18:28Z","timestamp":1378984708000},"page":"81-91","source":"Crossref","is-referenced-by-count":102,"title":["In Vitro and In Vivo Efficacy of SYL040012, a Novel siRNA Compound for Treatment of Glaucoma"],"prefix":"10.1016","volume":"22","author":[{"given":"Tamara","family":"Mart\u00ednez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Victoria","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingo","family":"Roehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Covadonga","family":"Pa\u00f1eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Isabel","family":"Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/mt.2013.216_bib1","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(10)61423-7","article-title":"Glaucoma","volume":"377","author":"Quigley","year":"2011","journal-title":"Lancet"},{"key":"10.1038\/mt.2013.216_bib2","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.ajo.2011.06.004","article-title":"An assessment of the health and economic burdens of glaucoma","volume":"152","author":"Varma","year":"2011","journal-title":"Am J Ophthalmol"},{"key":"10.1038\/mt.2013.216_bib3","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1001\/archopht.120.6.701","article-title":"The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma","volume":"120","author":"Kass","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"10.1038\/mt.2013.216_bib4","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.ajo.2011.05.029","article-title":"Intraocular pressure: modulation as treatment for glaucoma","volume":"152","author":"Caprioli","year":"2011","journal-title":"Am J Ophthalmol"},{"key":"10.1038\/mt.2013.216_bib5","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1136\/bmj.328.7431.97","article-title":"Glaucoma\u20131: diagnosis","volume":"328","author":"Khaw","year":"2004","journal-title":"BMJ"},{"key":"10.1038\/mt.2013.216_bib6","doi-asserted-by":"crossref","first-page":"52","DOI":"10.2174\/1874364101004010052","article-title":"Aqueous humor dynamics: a review","volume":"4","author":"Goel","year":"2010","journal-title":"Open Ophthalmol J"},{"key":"10.1038\/mt.2013.216_bib7","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/archopht.120.10.1268","article-title":"Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial","volume":"120","author":"Heijl","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"10.1038\/mt.2013.216_bib8","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2217\/17410541.5.4.377","article-title":"Pharmacogenetics of ophthalmic topical beta-blockers","volume":"5","author":"Sidjanin","year":"2008","journal-title":"Per Med"},{"key":"10.1038\/mt.2013.216_bib9","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/CRD.0b013e318156ec64","article-title":"Cardiovascular and respiratory considerations with pharmacotherapy of glaucoma and ocular hypertension","volume":"16","author":"Han","year":"2008","journal-title":"Cardiol Rev"},{"key":"10.1038\/mt.2013.216_bib10","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1080\/00365510601034736","article-title":"Ophthalmic timolol: plasma concentration and systemic cardiopulmonary effects","volume":"67","author":"Nieminen","year":"2007","journal-title":"Scand J Clin Lab Invest"},{"key":"10.1038\/mt.2013.216_bib11","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1089\/jop.1993.9.373","article-title":"Topical ophthalmic beta blockers: a comparative review","volume":"9","author":"Zimmerman","year":"1993","journal-title":"J Ocul Pharmacol"},{"key":"10.1038\/mt.2013.216_bib12","first-page":"420","article-title":"Distribution and properties of beta-adrenergic receptors in human iris-ciliary body","volume":"28","author":"Wax","year":"1987","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1038\/mt.2013.216_bib13","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1089\/jop.1990.6.143","article-title":"Beta adrenergic binding sites in the human eye: an autoradiographic study","volume":"6","author":"Elena","year":"1990","journal-title":"J Ocul Pharmacol"},{"key":"10.1038\/mt.2013.216_bib14","first-page":"1436","article-title":"Autoradiographic localization of beta-adrenergic receptors in rabbit eye","volume":"28","author":"Elena","year":"1987","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1038\/mt.2013.216_bib15","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1136\/bjo.66.12.788","article-title":"Beta adrenergic receptors in pigmented ciliary processes","volume":"66","author":"Trope","year":"1982","journal-title":"Br J Ophthalmol"},{"key":"10.1038\/mt.2013.216_bib16","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/35888","article-title":"Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans","volume":"391","author":"Fire","year":"1998","journal-title":"Nature"},{"key":"10.1038\/mt.2013.216_bib17","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1093\/emboj\/17.9.2637","article-title":"Selection in vitro of novel ribozymes from a partially randomized U2 and U6 snRNA library","volume":"17","author":"Tuschl","year":"1998","journal-title":"EMBO J"},{"key":"10.1038\/mt.2013.216_bib18","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0092-8674(00)80620-0","article-title":"RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals","volume":"101","author":"Zamore","year":"2000","journal-title":"Cell"},{"key":"10.1038\/mt.2013.216_bib19","first-page":"117","article-title":"In vivo application of RNA interference: from functional genomics to therapeutics","volume":"54","author":"Lu","year":"2005","journal-title":"Adv Genet"},{"key":"10.1038\/mt.2013.216_bib20","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2165\/11318190-000000000-00000","article-title":"RNA interference technologies and therapeutics: from basic research to products","volume":"23","author":"L\u00f3pez-Fraga","year":"2009","journal-title":"BioDrugs"},{"key":"10.1038\/mt.2013.216_bib21","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/mt.2013.31","article-title":"Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection","volume":"21","author":"Wooddell","year":"2013","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2013.216_bib22","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.ymthe.2006.01.001","article-title":"Progress towards in vivo use of siRNAs","volume":"13","author":"Behlke","year":"2006","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2013.216_bib23","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/sj.gt.3302653","article-title":"Potential applications for RNAi to probe pathogenesis and develop new treatments for ocular disorders","volume":"13","author":"Campochiaro","year":"2006","journal-title":"Gene Ther"},{"key":"10.1038\/mt.2013.216_bib24","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1089\/nat.2012.0399","article-title":"Oligo safety working group exaggerated pharmacology subcommittee consensus document","volume":"23","author":"Kornbrust","year":"2013","journal-title":"Nucleic Acid Ther"},{"key":"10.1038\/mt.2013.216_bib25","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nature04791","article-title":"Fatality in mice due to oversaturation of cellular microRNA\/short hairpin RNA pathways","volume":"441","author":"Grimm","year":"2006","journal-title":"Nature"},{"key":"10.1038\/mt.2013.216_bib26","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0092-8674(01)00547-5","article-title":"ATP requirements and small interfering RNA structure in the RNA interference pathway","volume":"107","author":"Nyk\u00e4nen","year":"2001","journal-title":"Cell"},{"key":"10.1038\/mt.2013.216_bib27","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1358\/mf.2007.29.10.1147765","article-title":"Comparative efficacy of pilocarpine, timolol and latanoprost in experimental models of glaucoma","volume":"29","author":"Gupta","year":"2007","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"10.1038\/mt.2013.216_bib28","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0160-5402(90)90019-H","article-title":"Transitory models of experimentally induced intraocular pressure changes in the rabbit. A reappraisal","volume":"24","author":"Hariton","year":"1990","journal-title":"J Pharmacol Methods"},{"key":"10.1038\/mt.2013.216_bib29","first-page":"781","article-title":"An improved model of experimentally induced ocular hypertension in the rabbit","volume":"15","author":"Bonomi","year":"1976","journal-title":"Invest Ophthalmol"},{"key":"10.1038\/mt.2013.216_bib30","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0306-3623(98)00196-7","article-title":"The effect of topical diltiazem on ocular hypertension induced by water loading in rabbits","volume":"32","author":"Santaf\u00e9","year":"1999","journal-title":"Gen Pharmacol"},{"key":"10.1038\/mt.2013.216_bib31","first-page":"811","article-title":"Glaucoma is the second leading cause of blindness globally","volume":"82","author":"Kingman","year":"2004","journal-title":"Bull World Health Organ"},{"issue":"suppl. 2","key":"10.1038\/mt.2013.216_bib32","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.1016\/S0039-6257(97)80016-1","article-title":"Phase III latanoprost studies in Scandinavia, the United Kingdom and the United States","volume":"41","author":"Alm","year":"1997","journal-title":"Surv Ophthalmol"},{"key":"10.1038\/mt.2013.216_bib33","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2165\/11588830-000000000-00000","article-title":"Effects of common topical antiglaucoma medications on the ocular surface, eyelids and periorbital tissue","volume":"28","author":"Servat","year":"2011","journal-title":"Drugs Aging"},{"key":"10.1038\/mt.2013.216_bib34","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/IJG.0b013e3181e0791c","article-title":"Efficiency of glaucoma drug regulation in 5 European countries: a 1995-2006 longitudinal prescription analysis","volume":"20","author":"De Natale","year":"2011","journal-title":"J Glaucoma"},{"key":"10.1038\/mt.2013.216_bib35","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.addr.2007.03.005","article-title":"RNAi therapeutics: principles, prospects and challenges","volume":"59","author":"Aagaard","year":"2007","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1038\/mt.2013.216_bib36","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nature03121","article-title":"Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs","volume":"432","author":"Soutschek","year":"2004","journal-title":"Nature"},{"key":"10.1038\/mt.2013.216_bib37","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0022-3565(25)20057-X","article-title":"Differential inhibition of beta adrenergic receptors in human and rabbit ciliary process and heart","volume":"232","author":"Nathanson","year":"1985","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1038\/mt.2013.216_bib38","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1248\/bpb.28.65","article-title":"Potent reduction of intraocular pressure by nipradilol plus latanoprost in ocular hypertensive rabbits","volume":"28","author":"Orihashi","year":"2005","journal-title":"Biol Pharm Bull"},{"key":"10.1038\/mt.2013.216_bib39","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1038\/cddis.2011.54","article-title":"Ocular neuroprotection by siRNA targeting caspase-2","volume":"2","author":"Ahmed","year":"2011","journal-title":"Cell Death Dis"},{"key":"10.1038\/mt.2013.216_bib40","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ajo.2010.02.006","article-title":"RNAi-based treatment for neovascular age-related macular degeneration by Sirna-027","volume":"150","author":"Kaiser","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"10.1038\/mt.2013.216_bib41","first-page":"210","article-title":"Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model","volume":"9","author":"Reich","year":"2003","journal-title":"Mol Vis"},{"key":"10.1038\/mt.2013.216_bib42","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/sj.gt.3302641","article-title":"Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1","volume":"13","author":"Shen","year":"2006","journal-title":"Gene Ther"},{"key":"10.1038\/mt.2013.216_bib43","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/mt.2011.212","article-title":"Short-interfering RNAs induce retinal degeneration via TLR3 and IRF3","volume":"20","author":"Kleinman","year":"2012","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2013.216_bib44","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nature06765","article-title":"Sequence- and target-independent angiogenesis suppression by siRNA via TLR3","volume":"452","author":"Kleinman","year":"2008","journal-title":"Nature"},{"key":"10.1038\/mt.2013.216_bib45","series-title":"Pharmacology of the Eye","first-page":"19","article-title":"Ocular pharmacokinetics","author":"Sears","year":"1984"},{"key":"10.1038\/mt.2013.216_bib46","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.addr.2006.07.027","article-title":"Challenges and obstacles of ocular pharmacokinetics and drug delivery","volume":"58","author":"Urtti","year":"2006","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1038\/mt.2013.216_bib47","first-page":"584","article-title":"Importance of the noncorneal absorption route in topical ophthalmic drug delivery","volume":"26","author":"Ahmed","year":"1985","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1038\/mt.2013.216_bib48","first-page":"684","article-title":"Paracellular permeability of corneal and conjunctival epithelia","volume":"30","author":"Huang","year":"1989","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1038\/mt.2013.216_bib49","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3109\/10611869808996838","article-title":"Comparison of the ocular distribution of a model oligonucleotide after topical instillation in rabbits of conventional and new dosage forms","volume":"6","author":"Bochot","year":"1998","journal-title":"J Drug Target"},{"key":"10.1038\/mt.2013.216_bib50","first-page":"627","article-title":"Characterization of paracellular and aqueous penetration routes in cornea, conjunctiva, and sclera","volume":"38","author":"H\u00e4m\u00e4l\u00e4inen","year":"1997","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1038\/mt.2013.216_bib51","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1167\/iovs.08-2372","article-title":"Efficient intraocular penetration of topical anti-TNF-alpha single-chain antibody (ESBA105) to anterior and posterior segment without penetration enhancer","volume":"50","author":"Ottiger","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1038\/mt.2013.216_bib52","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1089\/oli.2008.0149","article-title":"Stability study of unmodified siRNA and relevance to clinical use","volume":"18","author":"Hickerson","year":"2008","journal-title":"Oligonucleotides"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001616311224?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001616311224?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T14:37:33Z","timestamp":1746023853000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001616311224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["S1525001616311224"],"URL":"https:\/\/doi.org\/10.1038\/mt.2013.216","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]}}}